🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 16/02/2018 | 160,85 | 162,07 | 159,39 | 160,72 | -0,14% | 1,67% | 1.001.900 |
| 15/02/2018 | 158,36 | 161,08 | 157,16 | 160,94 | +2,34% | 2,48% | 1.244.700 |
| 14/02/2018 | 152,63 | 158,24 | 152,32 | 157,26 | +2,02% | 3,88% | 1.992.100 |
| 13/02/2018 | 151,40 | 155,49 | 150,99 | 154,14 | +1,40% | 2,97% | 1.624.500 |
| 12/02/2018 | 153,41 | 154,18 | 148,61 | 152,01 | -0,62% | 3,63% | 2.242.200 |
| 09/02/2018 | 152,92 | 154,63 | 146,21 | 152,96 | +0,90% | 5,51% | 2.719.800 |
| 08/02/2018 | 155,32 | 157,62 | 151,59 | 151,60 | -2,61% | 3,88% | 2.854.000 |
| 07/02/2018 | 157,10 | 160,11 | 155,62 | 155,67 | -2,26% | 2,86% | 1.812.900 |
| 06/02/2018 | 152,63 | 159,79 | 151,35 | 159,27 | +2,66% | 5,53% | 3.114.600 |
| 05/02/2018 | 163,08 | 165,87 | 155,03 | 155,14 | -6,68% | 6,65% | 2.906.900 |
| 02/02/2018 | 169,42 | 169,96 | 163,64 | 166,24 | -3,90% | 3,73% | 3.455.100 |
| 01/02/2018 | 174,11 | 174,96 | 163,17 | 172,99 | +3,67% | 6,77% | 5.090.000 |
| 31/01/2018 | 166,72 | 168,59 | 164,53 | 166,87 | +0,20% | 2,44% | 2.323.800 |
| 30/01/2018 | 166,37 | 168,08 | 164,00 | 166,54 | -0,36% | 2,45% | 2.184.600 |
| 29/01/2018 | 169,13 | 171,26 | 166,42 | 167,14 | -1,22% | 2,86% | 1.828.700 |
| 26/01/2018 | 167,14 | 169,30 | 166,10 | 169,21 | +1,79% | 1,91% | 1.495.100 |
| 25/01/2018 | 168,69 | 169,11 | 165,94 | 166,24 | -0,72% | 1,88% | 1.270.600 |
| 24/01/2018 | 167,08 | 169,29 | 165,38 | 167,45 | +0,52% | 2,34% | 2.492.700 |
| 23/01/2018 | 163,70 | 167,31 | 163,24 | 166,58 | +2,88% | 2,49% | 3.058.700 |
| 22/01/2018 | 158,76 | 161,95 | 157,98 | 161,91 | +2,49% | 2,50% | 1.689.000 |
| 19/01/2018 | 157,30 | 159,50 | 156,32 | 157,97 | +0,50% | 2,02% | 2.085.300 |
| 18/01/2018 | 156,36 | 157,51 | 154,22 | 157,19 | +0,13% | 2,10% | 1.250.900 |
| 17/01/2018 | 157,74 | 157,94 | 155,26 | 156,99 | +0,82% | 1,70% | 1.270.100 |
| 16/01/2018 | 158,28 | 159,87 | 155,14 | 155,71 | -1,41% | 2,99% | 1.834.800 |
| 12/01/2018 | 157,16 | 158,42 | 156,35 | 157,93 | -0,30% | 1,32% | 1.561.100 |
| 11/01/2018 | 158,00 | 159,05 | 156,62 | 158,40 | +0,65% | 1,54% | 950.600 |
| 10/01/2018 | 156,00 | 157,87 | 154,21 | 157,38 | +0,88% | 2,35% | 1.701.000 |
| 09/01/2018 | 156,81 | 157,88 | 154,51 | 156,01 | -0,56% | 2,15% | 1.487.700 |
| 08/01/2018 | 155,15 | 157,21 | 153,35 | 156,89 | +0,77% | 2,49% | 1.987.000 |
| 05/01/2018 | 155,54 | 157,35 | 154,10 | 155,69 | +1,71% | 2,09% | 1.940.000 |